Deal Snapshot
invoX Pharma to Acquire UK Drugmaker F-star Therapeutics for USD 161m
Monday 27 June 2022

London-based invoX Pharma, focussed on research and development and business development activities outside of China, has agreed to acquire all issued and outstanding shares of common stock of UK-based biopharmaceutical company F-star Therapeutics, Inc. (NASDAQ: FSTX) in a transaction that values F-star at approximately USD 161m, the company said.

invoX Pharma is a wholly owned subsidiary of Sino Biopharmaceutical Ltd. (HKEX 1177 HK). The proposed USD 161m all-cash acquisition will accelerate invoX's strategy to build Sino Biopharm's International Biopharmaceutical R and D Platform outside of China.

Date Published: 27/06/2022